phosphate sodium (oral)
500mg elemental phosphorus tablets

Note:
This guideline provides advice of a general nature. This statewide guideline has been prepared to promote and facilitate standardisation and consistency of practice, using a multidisciplinary approach. The guideline is based on a review of published evidence and expert opinion.

Information in this statewide guideline is current at the time of publication.

SA Health does not accept responsibility for the quality or accuracy of material on websites linked from this site and does not sponsor, approve or endorse materials on such links.

Health practitioners in the South Australian public health sector are expected to review specific details of each patient and professionally assess the applicability of the relevant guideline to that clinical situation.

If for good clinical reasons, a decision is made to depart from the guideline, the responsible clinician must document in the patient’s medical record, the decision made, by whom, and detailed reasons for the departure from the guideline.

This statewide guideline does not address all the elements of clinical practice and assumes that the individual clinicians are responsible for discussing care with consumers in an environment that is culturally appropriate and which enables respectful confidential discussion. This includes:

- The use of interpreter services where necessary.
- Advising consumers of their choice and ensuring informed consent is obtained.
- Providing care within scope of practice, meeting all legislative requirements and maintaining standards of professional conduct, and
- Documenting all care in accordance with mandatory and local requirements.

Note
Phosphate sodium tablets (Phosphate-Sandoz®) contain 500 mg of elemental phosphorous (equivalent to 16.1mmol phosphate) and must be dispersed in water.

Dose and Indications

Treatment for hypophosphataemia and osteopenia of prematurity

Oral

Doses should always be expressed as mmol of phosphate

0.5mmol/kg/dose, given 2 to 3 times a day

Adjust according to calcium and phosphate levels

Preparation and Administration

Oral

There are TWO STEPS to this process.

<table>
<thead>
<tr>
<th>Dose</th>
<th>0.25mmol</th>
<th>0.5mmol</th>
<th>0.75mmol</th>
<th>1.0mmol</th>
<th>1.25mmol</th>
</tr>
</thead>
<tbody>
<tr>
<td>Volume</td>
<td>0.25mL</td>
<td>0.5mL</td>
<td>0.75mL</td>
<td>1.0mL</td>
<td>1.25mL</td>
</tr>
</tbody>
</table>
Adverse Effects

**Common**
Nausea, diarrhoea.

**Infrequent**
Hypotension, oedema, hypocalcaemia

**Monitoring**
- Serum phosphate, calcium, sodium and potassium levels.

**Practice Points**
- Doses should be adjusted accordingly to maintain plasma phosphate levels at approximately 2mmol/L.
- Consideration should be given to the sodium and potassium content of Phosphate-Sandoz® tablets in cases of electrolyte imbalance.
- Each tablet also provides sodium 469mg (equivalent to 20.4mmol), potassium 123mg (equivalent to 3.1mmol).
- Separate from calcium salts by TWO hours, as concurrent administration may reduce absorption due to binding and formation of insoluble salts.
phosphate sodium (oral)
500mg elemental phosphorus tablets

Document Ownership & History

Developed by: SA Maternal, Neonatal & Gynaecology Community of Practice
Contact: Health.NeoMed@sa.gov.au
Endorsed by: SA Health Safety and Quality Strategic Governance Committee
Next review due: 31/05/2020
ISBN number: 978-1-74243-409-4
PDS reference: CG107
Policy history:

<table>
<thead>
<tr>
<th>Approval Date</th>
<th>Version</th>
<th>Who approved New/Revised Version</th>
<th>Reason for Change</th>
</tr>
</thead>
<tbody>
<tr>
<td>9/03/2018</td>
<td>V3.1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Review date extended to 5 years following risk assessment. New template.</td>
</tr>
<tr>
<td>03/2015</td>
<td>V3</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed version</td>
</tr>
<tr>
<td>10/2014</td>
<td>V2</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Reviewed version</td>
</tr>
<tr>
<td>09/2014</td>
<td>V1</td>
<td>SA Health Safety and Quality Strategic Governance Committee</td>
<td>Original SA Health Safety and Quality Strategic Governance Committee approved version</td>
</tr>
</tbody>
</table>

Is this a new policy (V1)?  N
Does this policy amend or update an existing policy?  Y
If so, which version?  2.0
Does this policy replace another policy with a different title?  N
If so, which policy (title)?